Lacey David L, Boyle William J, Simonet W Scott, Kostenuik Paul J, Dougall William C, Sullivan John K, San Martin Javier, Dansey Roger   Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nature reviews. Drug discovery, 2012; 11(5): 401-19.

Bowers Peter M, Horlick Robert A, Neben Tamlyn Y, Toobian Rachelle M, Tomlinson Geoffrey L, Dalton Jennifer L, Jones Heather A, Chen Andy, Altobell Laurence, Zhang Xue, Macomber John L, Krapf Irina P, Wu Betty F, McConnell Audrey, Chau Betty, Holland Trevin, Berkebile Ashley D, Neben Steven S, Boyle William J, King David J   Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies Proceedings of the National Academy of Sciences of the United States of America, 2011; 108(51): 20455-60.

Bornstein Gadi Gazit, Klakamp Scott L, Andrews Laura, Boyle William J, Tabrizi Mohammad   Surrogate approaches in development of monoclonal antibodies Drug discovery today, 2009; 14(23-24): 1159-65.

Kostenuik Paul J, Nguyen Hung Q, McCabe James, Warmington Kelly S, Kurahara Carol, Sun Ning, Chen Ching, Li Luke, Cattley Russ C, Van Gwyneth, Scully Shelia, Elliott Robin, Grisanti Mario, Morony Sean, Tan Hong Lin, Asuncion Frank, Li Xiaodong, Ominsky Michael S, Stolina Marina, Dwyer Denise, Dougall William C, Hawkins Nessa, Boyle William J, Simonet William S, Sullivan John K   Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2009; 24(2): 182-95.

Kwak Keith S, Zhou Xiaolan, Solomon Vered, Baracos Vickie E, Davis James, Bannon Anthony W, Boyle William J, Lacey David L, Han H Q   Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia Cancer research, 2004; 64(22): 8193-8.

Boyle William J, Simonet W Scott, Lacey David L   Osteoclast differentiation and activation Nature, 2003; 423(6937): 337-42.

Eghbali-Fatourechi Guitty, Khosla Sundeep, Sanyal Arunik, Boyle William J, Lacey David L, Riggs B Lawrence   Role of RANK ligand in mediating increased bone resorption in early postmenopausal women The Journal of clinical investigation, 2003; 111(8): 1221-30.

Bolon Brad, Shalhoub Victoria, Kostenuik Paul J, Campagnuolo Giuseppe, Morony Sean, Boyle William J, Zack Debra, Feige Ulrich   Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis Arthritis and rheumatism, 2002; 46(12): 3121-35.

Theill Lars E, Boyle William J, Penninger Josef M   RANK-L and RANK: T cells, bone loss, and mammalian evolution Annual review of immunology, 2002; 20(12): 795-823.

Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman S A, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle W J, Lacey D L   Characterization of osteoclast precursors in human blood British journal of haematology, 2000; 111(2): 501-12.

Lacey D L, Tan H L, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess T L, Boyle W J, Polverino A J   Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo The American journal of pathology, 2000; 157(2): 435-48.

Min H, Morony S, Sarosi I, Dunstan C R, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik P J, Lacey D L, Boyle W J, Simonet W S   Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis The Journal of experimental medicine, 2000; 192(4): 463-74.